SLC5A2 and polycystic ovary syndrome: SGLT‐2 inhibitors are also promising therapeutics that have been shown significant advantages in improving metabolic abnormalities in women with PCOS, however their roles and pathways in improving PCOS metabolic and hormonal disturbances need further studies.